David Solomon Williams III Sells 5,000 Shares of AdaptHealth (NASDAQ:AHCO) Stock

AdaptHealth Corp. (NASDAQ:AHCO) Director David Solomon Williams III sold 5,000 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $9.43, for a total transaction of $47,150.00. Following the completion of the transaction, the director directly owned 45,045 shares of the company’s stock, valued at $424,774.35. The trade was a 9.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

AdaptHealth Trading Up 0.4%

Shares of AdaptHealth stock traded up $0.04 during mid-day trading on Friday, hitting $9.42. 506,701 shares of the stock were exchanged, compared to its average volume of 1,289,076. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of 17.13, a price-to-earnings-growth ratio of 1.37 and a beta of 1.77. AdaptHealth Corp. has a twelve month low of $7.11 and a twelve month high of $11.63. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 1.09. The company has a 50-day simple moving average of $9.31 and a 200 day simple moving average of $9.20.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.05). The firm had revenue of $820.31 million for the quarter, compared to analysts’ expectations of $799.62 million. AdaptHealth had a net margin of 2.53% and a return on equity of 4.85%. The business’s quarterly revenue was up 1.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.15 EPS. Research analysts forecast that AdaptHealth Corp. will post 0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on AHCO shares. Wall Street Zen lowered shares of AdaptHealth from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Canaccord Genuity Group raised their price objective on AdaptHealth from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Zacks Research cut shares of AdaptHealth from a “hold” rating to a “strong sell” rating in a research report on Friday, September 19th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of AdaptHealth in a research note on Tuesday. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $13.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers purchased a new stake in AdaptHealth during the 1st quarter worth $208,000. XTX Topco Ltd acquired a new stake in shares of AdaptHealth during the first quarter valued at about $468,000. New Age Alpha Advisors LLC purchased a new stake in shares of AdaptHealth during the first quarter worth about $2,503,000. Charles Schwab Investment Management Inc. lifted its stake in shares of AdaptHealth by 14.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,301,652 shares of the company’s stock worth $14,110,000 after acquiring an additional 163,272 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in AdaptHealth in the first quarter valued at about $4,358,000. 82.67% of the stock is currently owned by hedge funds and other institutional investors.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.